Trial Profile
A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Cytarabine; Daunorubicin; Lomustine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms EPAG2015
- 13 Dec 2022 Results assessing impact on outcome of eltrombopag administered to elderly AML pts receiving induction chemotherapy presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 28 Jun 2021 Planned primary completion date changed from 1 Sep 2020 to 1 Jul 2022.
- 28 Jun 2021 Status changed from recruiting to active, no longer recruiting.